Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

By afschroeder • September 25, 2025

Le X, Robichaux JP, Nilsson M, Vijayan RSK, Ravichandran A, Wu J, Elamin YY, Hong L, Pei J, He J, Patel S, Udagawa H, Mani S, Jang CW, Clarke JM, Tchekmedyian N, Goldman JW, Socinski M, Bhat G, Leu S, Bunn V, Su Z, Vincent S, Lawson JW, Cross JB, Heymach JV. Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity. Nat Commun. 2025 Sep 24;16(1):8358. doi: 10.1038/s41467-025-61817-8. PMID: 40993146.

Tags: Hematology/Oncology, Publications

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein[...]

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium

Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, Coffey CS, Guo T, Haidar Y, Harris JP, Holsinger FC, Inman J, Jang[...]

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan[...]